IMUNON
Clinical trials sponsored by IMUNON, explained in plain language.
Clinical-stage biopharmaceutical company developing DNA-based immunotherapies and vaccines.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug combo aims to wipe out hidden ovarian cancer cells Results expected Jun 2027 (estimated)
-
New gene therapy combo aims to boost ovarian cancer survival
Disease control Recruiting nowThis phase 3 trial tests whether adding a gene therapy called IMNN-001 (given into the abdomen) to standard chemotherapy helps people with advanced ovarian, fallopian tube, or peritoneal cancer live longer. About 500 newly diagnosed patients will be randomly assigned to receive e…
Phase 3 • Sponsor: Imunon • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New drug combo aims to wipe out hidden ovarian cancer cells
Disease control Recruiting nowThis study tests whether adding the experimental drug IMNN-001 to standard chemotherapy and bevacizumab can better eliminate remaining cancer in people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer. About 30 participants will be randomly assi…
Phase 1/2 • Sponsor: Imunon • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC